GoAI
Get started
Novartis AG logo

Novartis AG

NVS

NYSEHealthcareDrug Manufacturers - General

Open in GoAI

Previous close

$158.86

+$2.62 · +1.68%

Aug 21, 4:00 PM ET

NVS company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Buy

Favorable setup — positive multi-factor alignment

Valuation

86

Deep Value

Momentum

50

Neutral

Sentiment

51

Mixed

Risk resilience

78

Moderate Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. Its product portfolio is heavily focused on innovative prescription medicines, especially oncology, immunology, neuroscience, and cardiovascular diseases, supplemented by established older brands and a wide range of specialized therapies. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Industry
Drug Manufacturers - General
Sector
Healthcare
Headquarters
CH
CEO
Vas Narasimhan
Listed since
Nov 7, 1996
Employees
75,267

Market position

Day range

Current $158.86

52-week range

Current $158.86

Open
$156.35
Previous close
$156.24
Volume
1.08M
0.63× average
Average volume
1.72M
Average daily volume
Market cap
301.95B USD
Beta
0.46
Market reference 1
50-day average
$154.33
+2.94% above average
200-day average
$148.25
+7.16% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
292.92B USD
P/E (TTM)
24.15×
P/B (TTM)
7.28×
P/S (TTM)
5.52×
EV / EBITDA
12.74×
Earnings yield
5.26%
Free cash flow yield
6.62%
Dividend yield
2.90%

Profitability & efficiency

Gross margin
74.29%
Operating margin
29.86%
Net margin
23.09%
Return on equity
30.47%
Return on assets
12.16%
Return on invested capital
15.50%

Financial health

Debt / equity
1.18×
Current ratio
1.12×

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends81%57%34%10%Gross margin, FY2021: 73.31%Gross margin, FY2022: 73.35%Gross margin, FY2023: 73.27%Gross margin, FY2024: 75.20%Gross margin, FY2025: 75.02%Operating margin, FY2021: 22.87%Operating margin, FY2022: 18.28%Operating margin, FY2023: 20.94%Operating margin, FY2024: 28.12%Operating margin, FY2025: 31.15%Net margin, FY2021: 54.63%Net margin, FY2022: 16.00%Net margin, FY2023: 31.83%Net margin, FY2024: 23.09%Net margin, FY2025: 25.64%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2021 73.31%. Gross margin FY2022 73.35%. Gross margin FY2023 73.27%. Gross margin FY2024 75.20%. Gross margin FY2025 75.02%. Operating margin FY2021 22.87%. Operating margin FY2022 18.28%. Operating margin FY2023 20.94%. Operating margin FY2024 28.12%. Operating margin FY2025 31.15%. Net margin FY2021 54.63%. Net margin FY2022 16.00%. Net margin FY2023 31.83%. Net margin FY2024 23.09%. Net margin FY2025 25.64%.

Income trends

Revenue

54.81B USD+5.97%

Operating income

17.07B USD+17.40%

Net income

14.06B USD+17.71%
Income trends across reported periods59.6B USD40.45B USD21.31B USD2.17B USDRevenue, FY2021: 43.97B USDRevenue, FY2022: 43.46B USDRevenue, FY2023: 46.66B USDRevenue, FY2024: 51.72B USDRevenue, FY2025: 54.81B USDOperating income, FY2021: 10.06B USDOperating income, FY2022: 7.95B USDOperating income, FY2023: 9.77B USDOperating income, FY2024: 14.54B USDOperating income, FY2025: 17.07B USDNet income, FY2021: 24.02B USDNet income, FY2022: 6.96B USDNet income, FY2023: 14.85B USDNet income, FY2024: 11.94B USDNet income, FY2025: 14.06B USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2021 43.97B USD. Revenue FY2022 43.46B USD. Revenue FY2023 46.66B USD. Revenue FY2024 51.72B USD. Revenue FY2025 54.81B USD. Operating income FY2021 10.06B USD. Operating income FY2022 7.95B USD. Operating income FY2023 9.77B USD. Operating income FY2024 14.54B USD. Operating income FY2025 17.07B USD. Net income FY2021 24.02B USD. Net income FY2022 6.96B USD. Net income FY2023 14.85B USD. Net income FY2024 11.94B USD. Net income FY2025 14.06B USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue54.81B USD51.72B USD46.66B USD43.46B USD43.97B USD
Cost of goods sold13.69B USD12.83B USD12.47B USD11.58B USD11.74B USD
Gross profit41.12B USD38.9B USD34.19B USD31.88B USD32.24B USD
Research and development10.74B USD10.02B USD11.37B USD9.17B USD8.64B USD
Selling, general, and administrative13.31B USD12.57B USD12.52B USD12.19B USD12.83B USD
Operating expenses24.05B USD24.35B USD24.42B USD23.93B USD22.18B USD
Interest income374.91M USD567.68M USD629.24M USD377.74M USD71M USD
Interest expense1.19B USD1.04B USD876.12M USD834.62M USD905M USD
Depreciation and amortization5.35B USD6.07B USD8.28B USD6.71B USD5.6B USD
Operating income17.07B USD14.54B USD9.77B USD7.95B USD10.06B USD
Net income14.06B USD11.94B USD14.85B USD6.96B USD24.02B USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
73%
8 beats, 3 misses, 0 met estimates
Average EPS surprise
+3.08%
11 comparable reports
Latest EPS result
2.41
Estimate 2.17 · Beat by 11.06%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates2.522.251.971.7Q1 '25BeatQ2 '25BeatQ3 '25BeatQ4 '25MissQ1 '26BeatQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 31, 2025: actual 1.98, estimate 1.8, surprise +10.00%, Beat. Q2 2025, reported Apr 29, 2025: actual 2.28, estimate 2.12, surprise +7.55%, Beat. Q3 2025, reported Jul 17, 2025: actual 2.42, estimate 2.38, surprise +1.68%, Beat. Q4 2025, reported Oct 28, 2025: actual 2.25, estimate 2.26, surprise -0.44%, Miss. Q1 2026, reported Feb 4, 2026: actual 2.03, estimate 1.99, surprise +2.01%, Beat. Q2 2026, reported Apr 28, 2026: actual 1.99, estimate 2.11, surprise -5.69%, Miss. Q3 2026, reported Jul 21, 2026: actual 2.41, estimate 2.17, surprise +11.06%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 2.21, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates15.18B14.2B13.23B12.25BQ1 '25BeatQ2 '25MissQ3 '25BeatQ4 '25BeatQ1 '26MissQ2 '26MissQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Jan 31, 2025: actual 13.56B USD, estimate 12.84B USD, surprise +5.61%, Beat. Q2 2025, reported Apr 29, 2025: actual 13.62B USD, estimate 13.9B USD, surprise -2.01%, Miss. Q3 2025, reported Jul 17, 2025: actual 14.28B USD, estimate 13.94B USD, surprise +2.47%, Beat. Q4 2025, reported Oct 28, 2025: actual 14.36B USD, estimate 13.64B USD, surprise +5.25%, Beat. Q1 2026, reported Feb 4, 2026: actual 13.34B USD, estimate 13.7B USD, surprise -2.69%, Miss. Q2 2026, reported Apr 28, 2026: actual 13.11B USD, estimate 13.44B USD, surprise -2.42%, Miss. Q3 2026, reported Jul 21, 2026: actual 14.41B USD, estimate 14.07B USD, surprise +2.43%, Beat. Q4 2026, reported Oct 27, 2026: actual —, estimate 14.59B USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$170

7.01% upside
Past 12 months12-month forecastHigh $170Average $170Low $170

Rating distribution

25 ratings
Strong buy00%
Buy624%
Hold1768%
Sell28%
Strong sell00%

Recent analyst actions

9 institutions
BarclaysupgradeUnderweightEqual Weight
JP MorganupgradeNeutralOverweight
UBSdowngradeBuyNeutral
Erste GroupdowngradeBuyHold
B of A SecuritiesdowngradeBuyNeutral

NVS news

247wallst.com

Why Novartis, Lilly, and Bristol Myers Are Eyeing This Clinical-Stage Cancer Play

Aktis Oncology (NASDAQ:AKTS) closed at $25.00 on August 18, 2026, giving the clinical-stage radiopharmaceutical company a market cap of $1.4 billion.

Read source
benzinga.com

Enliven's Lead Drug Could Disrupt The Leukemia Treatment Market, Analyst Says

Enliven Therapeutics Inc. (NASDAQ:ELVN) drew an Outperform rating from William Blair on Tuesday as the firm initiated coverage, citing the potential for lead drug candidate ELVN-001 to reshape treatment of chronic…

Read source
fool.com

PPH vs. IYH: Which Healthcare Fund Is the Better Buy?

PPH concentrates on just 26 drugmakers, while IYH diversifies more broadly across 100 healthcare holdings.

Read source
reuters.com

Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent

Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart drug ​Entresto, with London's High Court rejecting a claim by ‌Intas Pharmaceuticals' Accord Healthcare which was…

Read source
defenseworld.net

Axiom Investment Management LLC Takes Position in Novartis AG $NVS

Axiom Investment Management LLC purchased a new stake in shares of Novartis AG (NYSE: NVS) in the first quarter, according to its most recent filing with the SEC. The firm purchased 3,326 shares of the company's stock,…

Read source
defenseworld.net

Ashton Thomas Securities LLC Makes New Investment in Novartis AG $NVS

Ashton Thomas Securities LLC purchased a new stake in Novartis AG (NYSE: NVS) during the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor…

Read source

Corporate actions

Annual dividends per share

Cash distributions grouped by calendar year; partial years are marked.

$3.994

2025 complete year+24.8% since 2021

2026 partial: $4.7403

* Partial calendar year in the available dividend history.

Corporate action history

Dividend

Ex-dividend Mar 11, 2026

$4.7403

Annual

Record Mar 11, 2026 · Payment Mar 16, 2026

Dividend

Ex-dividend Mar 12, 2025

$3.994

Annual

Record Mar 12, 2025 · Payment Apr 25, 2025

Dividend

Ex-dividend Mar 7, 2024

$3.1986

Annual

Record Mar 8, 2024 · Payment Apr 19, 2024

Dividend

Ex-dividend Mar 9, 2023

$3.4987

Annual

Record Mar 10, 2023 · Payment Mar 20, 2023

Dividend

Ex-dividend Mar 8, 2022

$3.3253

Annual

Record Mar 9, 2022 · Payment Mar 17, 2022

Dividend

Ex-dividend Mar 4, 2021

$3.1991

Annual

Record Mar 5, 2021 · Payment Mar 15, 2021

NVS peers

Eli Lilly and Company logo

LLY

Eli Lilly and Company

$1,254.77

+0.83%

Johnson & Johnson logo

JNJ

Johnson & Johnson

$270.24

+1.07%

AbbVie Inc. logo

ABBV

AbbVie Inc.

$265.01

+1.21%

Merck & Co., Inc. logo

MRK

Merck & Co., Inc.

$152.55

+2.39%

UnitedHealth Group Incorporated logo

UNH

UnitedHealth Group Incorporated

$390.11

+1.37%

AstraZeneca PLC logo

AZN

AstraZeneca PLC

$165.98

+0.91%

ETFs holding NVS

Funds reporting this stock among their holdings, ordered by reported position size.

Dimensional - International Value ETF logoDimensional - International Value ETFDFIV
Market value
138.87M
Weight
0.64%
AUM
22.06B USD
Expense ratio
0.27%
Price / 1D
$58.31+0.88%
Dimensional - International Core Equity Market ETF logoDimensional - International Core Equity Market ETFDFAI
Market value
119.09M
Weight
0.66%
AUM
18.23B USD
Expense ratio
0.18%
Price / 1D
$43.35+0.81%
Dimensional - International Core Equity 2 ETF logoDimensional - International Core Equity 2 ETFDFIC
Market value
112.49M
Weight
0.73%
AUM
15.43B USD
Expense ratio
0.22%
Price / 1D
$39.405+0.83%
VanEck Pharmaceutical ETF logoVanEck Pharmaceutical ETFPPH
Market value
106.51M
Weight
10.08%
AUM
1.07B USD
Expense ratio
0.36%
Price / 1D
$116.63+1.35%
Avantis International Equity ETF logoAvantis International Equity ETFAVDE
Market value
104.2M
Weight
0.55%
AUM
19.1B USD
Expense ratio
0.23%
Price / 1D
$94.26+0.87%
Dimensional International High Profitability ETF logoDimensional International High Profitability ETFDIHP
Market value
91.86M
Weight
1.39%
AUM
6.65B USD
Expense ratio
0.27%
Price / 1D
$35.745+0.78%
Dimensional World ex U.S. Core Equity 2 ETF logoDimensional World ex U.S. Core Equity 2 ETFDFAX
Market value
80.95M
Weight
0.65%
AUM
12.57B USD
Expense ratio
0.28%
Price / 1D
$38.16+0.82%
Portfolio Building Block World Pharma and Biotech Index ETF logoPortfolio Building Block World Pharma and Biotech Index ETFPBPH
Market value
43.99M
Weight
4.21%
AUM
933.15M USD
Expense ratio
0.13%
Price / 1D
$29.5672+1.22%

Continue in GoAI

Research NVS

research.disclaimer